logo
Plus   Neg
Share
Email

Genentech: FDA Grants Priority Review For Rituxan In Pediatric Indication

Genentech, a member of the Roche Group (RHHBY), said the FDA has granted priority review for Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children above two years of age. Rituxan is currently approved for the treatment of four autoimmune indications.

The FDA accepted the company's sBLA which was based on data from the PePRS study, a Phase IIa, global study investigating intravenous Rituxan in 25 patients between six and 17 years of age.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple chief executive officer Tim Cook condemned the killing of an unarmed black man, George Floyd, and called for the creation of a "better, more just world for everyone," according to reports citing a memo to employees. Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining.
Follow RTT